Faeth Therapeutics (FTH): Betting On Multi-Node Blockade To Disrupt Cancer Growth

Faeth Therapeutics (FTH) is developing PIKTOR, a drug targeting the PAM pathway for cancer treatment. Despite a 75% stock drop, the company reports promising mid-stage trial results for endometrial cancer. Its cash position is expected to support upcoming clinical milestones.

Original reporting
Published Nov 16, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$FTH
Neutral
medium confidence
Mentioned
$FTH
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$FTHNeutralLow
01

Why it matters

The article introduces the first public mention of mid‑stage results for PIKTOR, a material development for the company.

02

Market read

New trial data for a micro‑cap biotech; modest trading relevance.

03

What to watch

Cash runway and upcoming milestones could become the dominant catalyst.

Relevance 5/10Novelty 7/10Timing: today

Background

Faeth Therapeutics (FTH) is a clinical‑stage biotech focused on multi‑node blockade of the PI3K/AKT/mTOR pathway.

Company-level read

Ticker impact

$FTHNeutralMedium confidence
Context

Faeth Therapeutics reported encouraging mid‑stage trial results for its lead candidate PIKTOR in advanced endometrial cancer, while its stock has fallen over 75% in two months.

Expected impact

likely modest upside as investors reassess risk, but overall pressure remains due to recent share decline

Evidence & confidence

First disclosure of trial data for a micro‑cap biotech; no quantitative efficacy numbers provided, so market reaction will be muted.

Market effects

adds modest optimism to the PI3K/AKT/mTOR targeted therapy space.

limited to US biotech investors.

low

Counterpoint

The stock may continue to slide if the trial data fails to meet expectations despite the positive tone.

Key entities

  • Faeth Therapeutics Inc.

    Biotech developing PIKTOR for endometrial and breast cancer.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.